American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Tallman
    Tallman
  5. Perales
    Perales
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Kernan
    Kernan
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3847)
  2. Hematologic Malignancies, Division of (3642)
  3. Center for Hematologic Malignancies (3544)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1290)
  6. Sloan Kettering Institute Faculty (1065)
  7. Bone Marrow Transplant (936)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (931)
  9. Lymphoma (899)
  10. Tow Center for Developmental Oncology (TCDO) (863)
Search Within
Formats
  1. Meeting Abstract (4152)
  2. Journal Article (1242)
  3. Research Letter (44)
  4. Review (44)
  5. Editorial (34)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3847)
  2. Hematologic Malignancies, Division of (3642)
  3. Center for Hematologic Malignancies (3544)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1290)
  6. Sloan Kettering Institute Faculty (1065)

More Groups

People
  1. Sergio Giralt (337)
  2. Andrew Zelenetz (328)
  3. Ross Levine (312)
  4. Martin Tallman (298)
  5. Miguel-Angel Perales (292)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (46)
  2. 2024 (430)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5167)
  2. Blood Advances (322)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5539)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High WEE1 expression correlates with poor survival in multiple myeloma, independent of standard prognostic factors
    Meeting Abstract

    Simhal, A. K.; Firestone, R. S.; Oh, J. H.; Norton, L.; Hultcrantz, M.; Usmani, S. Z.; Maclachlan, K. H.; Deasy, J. O.
    Blood (2024)

    Fulltext@MSK | Save
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Novel nilotinib tablet formulation: Pharmacokinetic characterization and effects of food
    Meeting Abstract

    Mauro, M. J.; Radich, J. P.; Jain, P.; Sequeira, D.; Douer, D.
    Blood (2024)

    Fulltext@MSK | Save
  • River-52: A multicenter, open-label clinical trial of RVU120 in patients with relapsed or refractory high-risk myelodysplastic syndrome or acute myeloid leukemia
    Meeting Abstract

    Papayannidis, C.; Madry, K.; Centkowski, P.; Prejzner, W.; Butrym, A.; Chraniuk, D.; Saba, C.; Angelosanto, N.; Curley, R.; Nogai, H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1, multicenter, open-label, dose-escalation study to evaluate safety, tolerability, pharmacokinetics, and clinical activity of orally administered LP-108 (lacutoclax) as monotherapy and in combination with azacitidine in subjects with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML)
    Meeting Abstract

    Burgues, J. M. B.; Koenig, K.; Montesinos, P.; Bixby, D. L.; Burke, P. W.; Daver, N.; Anthony, S. P.; Tan, F. L.; Chen, Y.; Chen, Y.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy of emavusertib (CA-4948) in combination with ibrutinib in relapsed/refractory primary central nervous system lymphoma patients with prior exposure to BTK inhibitor
    Meeting Abstract

    Nowakowski, G. S.; Dabrowska-Iwanicka, A. P.; Grommes, C.; Tun, H. W.; D'Angelo, C.; Burguera, A. D.; Levi, E.; Ramchandren, R.; Ferreri, A. J. M.; Choudhary, G. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study of nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, in combination with JAK inhibitors ruxolitinib or momelotinib in patients with myelofibrosis
    Meeting Abstract

    Mascarenhas, J. O.; Rampal, R.; El Chaer, F.; Gupta, V.; Shimoda, K.; Kiladjian, J. J.; Passamonti, F.; Bose, P.; Scandura, J. M.; Mesa, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • US expert consensus on defining intolerance to tyrosine kinase inhibitor treatment in chronic phase chronic myeloid leukemia (CML)
    Meeting Abstract

    Atallah, E. L.; Broder, M. S.; Chan, O.; Dalglish, H.; Flynn, K. E.; Gilreath, J.; Hine, M.; Hunter, A. M.; Mauro, M. J.; Pinilla-Ibarz, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world (RW) outcomes for brexucabtagene autoleucel (Brexu-Cel) treatment in patients (Pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) by high-risk features and prior treatments: Updated evidence from the CIBMTR® registry
    Meeting Abstract

    Wudhikarn, K.; Bezerra, E.; Yang, Y.; Perales, M. A.; Jain, N.; Gergis, U.; Aribi, A.; Hill, L.; Leonard, J. T.; Lutfi, F.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of novel therapies (NTs) on real-world (RW) clinical outcomes of patients (pts) with relapsed/refractory (RR) mantle-cell lymphoma (MCL) by race/ethnicity and TP53 mutation status
    Meeting Abstract

    Phillips, T. J.; Danilov, A. V.; Ruan, J.; Patel, K.; Kumar, A.; Wang, Y. C.; Maglinte, G. A.; Seymour, E.; Kamdar, M.
    Blood (2024)

    Fulltext@MSK | Save